{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,12,23]],"date-time":"2023-12-23T22:15:18Z","timestamp":1703369718975},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2014,5,17]],"date-time":"2014-05-17T00:00:00Z","timestamp":1400284800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Radiologe"],"published-print":{"date-parts":[[2014,6]]},"DOI":"10.1007\/s00117-013-2626-y","type":"journal-article","created":{"date-parts":[[2014,5,15]],"date-time":"2014-05-15T17:42:50Z","timestamp":1400175770000},"page":"545-550","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Interaktion zwischen Myelomzellen und Knochengewebe"],"prefix":"10.1007","volume":"54","author":[{"given":"A.","family":"Seckinger","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D.","family":"Hose","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,5,17]]},"reference":[{"key":"2626_CR1","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1182\/blood.V100.6.2195","volume":"100","author":"Abe","year":"2002","unstructured":"Abe M, Hiura K, Wilde J et al (2002) Role for macrophage inflammatory protein (MIP)-1\u03b1 and MIP-1\u03b2 in the development of osteolytic lesions in multiple myeloma. Blood 100:2195\u20132202","journal-title":"Blood"},{"key":"2626_CR2","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1182\/blood-2003-11-3839","volume":"104","author":"Abe","year":"2004","unstructured":"Abe M, Hiura K, Wilde J et al (2004) Osteoclasts enhance myeloma cell growth and survival via cell-cell contact: a vicious cycle between bone destruction and myeloma expansion. Blood 104:2484\u20132491","journal-title":"Blood"},{"key":"2626_CR3","doi-asserted-by":"crossref","first-page":"239","DOI":"10.2353\/ajpath.2009.080627","volume":"174","author":"Andersen","year":"2009","unstructured":"Andersen TL, Sondergaard TE, Skorzynska KE et al (2009) A physical mechanism for coupling bone resorption and formation in adult human bone. Am J Pathol 174:239\u2013247","journal-title":"Am J Pathol"},{"key":"2626_CR4","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1172\/JCI115305","volume":"88","author":"Bataille","year":"1991","unstructured":"Bataille R, Chappard D, Marcelli C et al (1991) Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. J Clin Invest 88:62\u201366","journal-title":"J Clin Invest"},{"key":"2626_CR5","first-page":"300","volume":"4","author":"Epstein","year":"2006","unstructured":"Epstein J, Walker R (2006) Myeloma and bone disease: \u201ethe dangerous tango\u201c. Clin Adv Hematol Oncol 4:300\u2013306","journal-title":"Clin Adv Hematol Oncol"},{"key":"2626_CR6","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.1182\/blood.V98.13.3527","volume":"98","author":"Giuliani","year":"2001","unstructured":"Giuliani N, Bataille R, Mancini C et al (2001) Myeloma cells induce imbalance in the osteoprotegerin\/osteoprotegerin ligand system in the human bone marrow environment. Blood 98:3527\u20133533","journal-title":"Blood"},{"key":"2626_CR7","doi-asserted-by":"crossref","first-page":"1606","DOI":"10.1200\/JCO.2009.25.5356","volume":"28","author":"Hillengass","year":"2010","unstructured":"Hillengass J, Fechtner K, Weber M-A et al (2010) Prognostic significance of focal lesions in whole-body magnetic resonance imaging in patients with asymptomatic multiple myeloma. J Clin Oncol 28:1606\u20131610","journal-title":"J Clin Oncol"},{"key":"2626_CR8","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/leu.2013.244","volume":"28","author":"Hillengass","year":"2014","unstructured":"Hillengass J, Weber MA, Kilk K et al (2014) Prognostic significance of whole-body MRI in patients with monoclonal gammopathy of undetermined significance. Leukemia 28:174\u2013178","journal-title":"Leukemia"},{"key":"2626_CR9","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2008-10-184226","volume":"114","author":"Hose","year":"2009","unstructured":"Hose D, Moreaux J, Meissner T et al (2009) Induction of angiogenesis by normal and malignant plasma cells. Blood 114:128\u2013143","journal-title":"Blood"},{"key":"2626_CR10","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3324\/haematol.2010.030296","volume":"96","author":"Hose","year":"2011","unstructured":"Hose D, Reme T, Hielscher T et al (2011) Proliferation is a central independent prognostic factor and target for personalized and risk adapted treatment in multiple myeloma. Haematologica 96:87\u201395","journal-title":"Haematologica"},{"key":"2626_CR11","doi-asserted-by":"crossref","first-page":"4331","DOI":"10.1182\/blood-2008-09-178350","volume":"113","author":"Hose","year":"2009","unstructured":"Hose D, R\u00e8me T, Meissner T et al (2009) Inhibition of aurora kinases for tailored risk-adapted treatment of multiple myeloma. Blood 113:4331\u20134340","journal-title":"Blood"},{"key":"2626_CR12","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/978-3-540-85772-3_3","volume":"183","author":"Klein","year":"2011","unstructured":"Klein B, Seckinger A, Moehler T et al (2011) Molecular pathogenesis of multiple myeloma: chromosomal aberrations, changes in gene expression, cytokine networks, and the bone marrow microenvironment. Recent Results Cancer Res 183:39\u201386","journal-title":"Recent Results Cancer Res"},{"key":"2626_CR13","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","volume":"78","author":"Kyle","year":"2003","unstructured":"Kyle RA, Gertz MA, Witzig TE et al (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 78:21\u201333","journal-title":"Mayo Clin Proc"},{"key":"2626_CR14","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1359\/JBMR.041131","volume":"20","author":"Melton","year":"2005","unstructured":"Melton LJ, Kyle RA, Achenbach SJ et al (2005) Fracture risk with multiple myeloma: a population-based study. J Bone Miner Res 20:487\u2013493","journal-title":"J Bone Miner Res"},{"key":"2626_CR15","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1172\/JCI6374","volume":"103","author":"Menaa","year":"1999","unstructured":"Menaa C, Devlin RD, Reddy SV et al (1999) Annexin II increases osteoclast formation by stimulating the proliferation of osteoclast precursors in human marrow cultures. J Clin Invest 103:1605\u20131613","journal-title":"J Clin Invest"},{"key":"2626_CR16","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s00223-010-9372-1","volume":"87","author":"Moester","year":"2010","unstructured":"Moester MJ, Papapoulos SE, Lowik CW et al (2010) Sclerostin: current knowledge and future perspectives. Calcif Tissue Int 87:99\u2013107","journal-title":"Calcif Tissue Int"},{"key":"2626_CR17","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1182\/blood-2010-04-279760","volume":"117","author":"Moreaux","year":"2011","unstructured":"Moreaux J, Hose D, Kassambara A et al (2011) Osteoclast-gene expression profiling reveals osteoclast-derived CCR2-chemokines promoting myeloma cell migration. Blood 117:1280\u20131290","journal-title":"Blood"},{"key":"2626_CR18","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/j.1600-0609.2009.01262.x","volume":"83","author":"Moreaux","year":"2009","unstructured":"Moreaux J, Sprynski A-C, Dillon SR et al (2009) APRIL and TACI interact with syndecan-1 on the surface of multiple myeloma cells to form an essential survival loop. Eur J Haematol 83:119\u2013129","journal-title":"Eur J Haematol"},{"key":"2626_CR19","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1016\/S0140-6736(10)62051-X","volume":"376","author":"Morgan","year":"2010","unstructured":"Morgan GJ, Davies FE, Gregory WM et al (2010) First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial. Lancet 376:1989\u20131999","journal-title":"Lancet"},{"key":"2626_CR20","doi-asserted-by":"crossref","first-page":"4325","DOI":"10.1200\/JCO.2012.48.4923","volume":"31","author":"Neben","year":"2013","unstructured":"Neben K, Jauch A, Hielscher T et al (2013) Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del(17p), t(4;14), Gain 1q, hyperdiploidy, and tumor load. J Clin Oncol 31:4325\u20134332","journal-title":"J Clin Oncol"},{"key":"2626_CR21","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1084\/jem.190.2.293","volume":"190","author":"Niida","year":"1999","unstructured":"Niida S, Kaku M, Amano H et al (1999) Vascular endothelial growth factor can substitute for macrophage colony-stimulating factor in the support of osteoclastic bone resorption. J Exp Med 190:293\u2013298","journal-title":"J Exp Med"},{"key":"2626_CR22","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1002\/cncr.22991","volume":"110","author":"Saad","year":"2007","unstructured":"Saad F, Lipton A, Cook R et al (2007) Pathologic fractures correlate with reduced survival in patients with malignant bone disease. Cancer 110:1860\u20131867","journal-title":"Cancer"},{"key":"2626_CR23","doi-asserted-by":"crossref","unstructured":"Seckinger A, Mei\u00dfner T, Bertsch U et al (2013) Bone turnover in multiple myeloma: impact of bortezomib-based induction therapy, high-dose melphalan, and lenalidomide consolidation on osteoblast and osteoclast function within the GMMG-MM5 Trial. ASH Annual Meeting Abstracts 1863","DOI":"10.1182\/blood.V122.21.1863.1863"},{"key":"2626_CR24","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1182\/blood-2012-03-415588","volume":"120","author":"Seckinger","year":"2012","unstructured":"Seckinger A, Mei\u00dfner T, Moreaux J et al (2012) Clinical and prognostic role of annexin A2 in multiple myeloma. Blood 120:1087\u20131094","journal-title":"Blood"},{"key":"2626_CR25","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1038\/onc.2009.257","volume":"28","author":"Seckinger","year":"2009","unstructured":"Seckinger A, Meissner T, Moreaux J et al (2009) Bone morphogenic protein 6: a member of a novel class of prognostic factors expressed by normal and malignant plasma cells inhibiting proliferation and angiogenesis. Oncogene 28:3866\u20133879","journal-title":"Oncogene"},{"key":"2626_CR26","first-page":"912","volume":"63","author":"Shipman","year":"2003","unstructured":"Shipman CM, Croucher PI (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand\/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res 63:912\u2013916","journal-title":"Cancer Res"},{"key":"2626_CR27","doi-asserted-by":"crossref","first-page":"4614","DOI":"10.1182\/blood-2008-07-170464","volume":"113","author":"Sprynski","year":"2009","unstructured":"Sprynski AC, Hose D, Caillot L et al (2009) The role of IGF-1 as a major growth factor for myeloma cell lines and the prognostic relevance of the expression of its receptor. Blood 113:4614\u20134626","journal-title":"Blood"},{"key":"2626_CR28","doi-asserted-by":"crossref","first-page":"3024","DOI":"10.1182\/blood-2006-07-034884","volume":"109","author":"Standal","year":"2007","unstructured":"Standal T, Abildgaard N, Fagerli U-M et al (2007) HGF inhibits BMP-induced osteoblastogenesis: possible implications for the bone disease of multiple myeloma. Blood 109:3024\u20133030","journal-title":"Blood"},{"key":"2626_CR29","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1002\/jcb.10613","volume":"90","author":"Sugatani","year":"2003","unstructured":"Sugatani T, Alvarez UM, Hruska KA (2003) Activin A stimulates IkappaB-alpha\/NFkappaB and RANK expression for osteoclast differentiation, but not AKT survival pathway in osteoclast precursors. J Cell Biochem 90:59\u201367","journal-title":"J Cell Biochem"},{"key":"2626_CR30","first-page":"5850","volume":"63","author":"Tai","year":"2003","unstructured":"Tai Y-T, Podar K, Catley L et al (2003) Insulin-like growth factor-1 induces adhesion and migration in human multiple myeloma cells via activation of beta1-integrin and phosphatidylinositol 3\u2019-kinase\/AKT signaling. Cancer Res 63:5850\u20135858","journal-title":"Cancer Res"},{"key":"2626_CR31","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1158\/1078-0432.CCR-06-2258","volume":"13","author":"Tanaka","year":"2007","unstructured":"Tanaka Y, Abe M, Hiasa M et al (2007) Myeloma cell-osteoclast interaction enhances angiogenesis together with bone resorption: a role for vascular endothelial cell growth factor and osteopontin. Clin Cancer Res 13:816\u2013823","journal-title":"Clin Cancer Res"},{"key":"2626_CR32","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1586\/17474086.2013.874943","volume":"7","author":"Terpos","year":"2014","unstructured":"Terpos E, Berenson J, Raje N et al (2014) Management of bone disease in multiple myeloma. Expert Rev Hematol 7:113\u2013125","journal-title":"Expert Rev Hematol"},{"key":"2626_CR33","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1002\/ajh.23577","volume":"89","author":"Terpos","year":"2014","unstructured":"Terpos E, Christoulas D, Kastritis E et al (2014) The combination of lenalidomide and dexamethasone reduces bone resorption in responding patients with relapsed\/refractory multiple myeloma but has no effect on bone formation: final results on 205 patients of the Greek myeloma study group. Am J Hematol 89:34\u201340","journal-title":"Am J Hematol"},{"key":"2626_CR34","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1002\/ijc.27342","volume":"131","author":"Terpos","year":"2011","unstructured":"Terpos E, Christoulas D, Katodritou E et al (2011) Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma; reduction post-bortezomib monotherapy. Int J Cancer 131:1466\u20131471","journal-title":"Int J Cancer"},{"key":"2626_CR35","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1093\/annonc\/mds068","volume":"23","author":"Terpos","year":"2012","unstructured":"Terpos E, Kastritis E, Christoulas D et al (2012) Circulating activin-A is elevated in patients with advanced multiple myeloma and correlates with extensive bone involvement and inferior survival; no alterations post-lenalidomide and dexamethasone therapy. Ann Oncol 23:2681\u20132686","journal-title":"Ann Oncol"},{"key":"2626_CR36","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1200\/JCO.2012.47.7901","volume":"31","author":"Terpos","year":"2013","unstructured":"Terpos E, Morgan G, Dimopoulos MA et al (2013) International Myeloma Working Group recommendations for the treatment of multiple myeloma-related bone disease. J Clin Oncol 31:2347\u20132357","journal-title":"J Clin Oncol"},{"key":"2626_CR37","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1182\/blood-2003-02-0380","volume":"102","author":"Terpos","year":"2003","unstructured":"Terpos E, Szydlo R, Apperley JF et al (2003) Soluble receptor activator of nuclear factor \u03baB ligand \u2013 osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. Blood 102:1064\u20131069","journal-title":"Blood"},{"key":"2626_CR38","doi-asserted-by":"crossref","first-page":"2483","DOI":"10.1056\/NEJMoa030847","volume":"349","author":"Tian","year":"2003","unstructured":"Tian E, Zhan F, Walker R et al (2003) The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 349:2483\u20132494","journal-title":"N Engl J Med"},{"key":"2626_CR39","doi-asserted-by":"crossref","first-page":"5124","DOI":"10.1073\/pnas.0911929107","volume":"107","author":"Vallet","year":"2010","unstructured":"Vallet S, Mukherjee S, Vaghela N et al (2010) Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease. Proc Natl Acad Sci U S A 107:5124\u20135129","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2626_CR40","doi-asserted-by":"crossref","unstructured":"Moehler T, Goldschmidt H (Hrsg) (2011) Multiple myeloma, 39 recent results in cancer research 183, Kap 3. Springer, Berlin Heidelberg New York, S\u00a061. doi:10.1007\/978-3-540-85772-3_3","DOI":"10.1007\/978-3-540-85772-3_3"}],"container-title":["Der Radiologe"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-013-2626-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00117-013-2626-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00117-013-2626-y","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T13:19:54Z","timestamp":1597843194000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00117-013-2626-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,17]]},"references-count":40,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2014,6]]}},"alternative-id":["2626"],"URL":"https:\/\/doi.org\/10.1007\/s00117-013-2626-y","relation":{},"ISSN":["0033-832X","1432-2102"],"issn-type":[{"value":"0033-832X","type":"print"},{"value":"1432-2102","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,17]]}}}